This comprehensive account of the human herpesviruses provides an encyclopedic overview of their basic virology and clinical manifestations. This group of viruses includes human simplex type 1 and 2, Epstein–Barr virus, Kaposi's Sarcoma-associated herpesvirus, cytomegalovirus, HHV6A, 6B and 7, and varicella-zoster virus. The viral diseases and cancers they cause are significant and often recurrent. Their prevalence in the developed world accounts for a major burden of disease, and as a result there is a great deal of research into the pathophysiology of infection and immunobiology. Another important area covered within this volume concerns antiviral therapy and the development of vaccines. All these aspects are covered in depth, both scientifically and in terms of clinical guidelines for patient care. The text is illustrated generously throughout and is fully referenced to the latest research and developments.

" . . . the motto for the therapeutics of the future will have to be de sedibus et causis pharmacorum. " P. EHRLICH, 1909 Exciting events in the basic disciplines of virology, immunology, and pharmacology continue to advance the understanding of the pathogenesis and control of virus diseases. At the same time, the rational development of antiviral agents is attracting, to an increasing extent, the interest of workers in other disciplines. Improvements in technology facilitate the definition of potential target sites for antiviral intervention and unmask new viral and host genes. The outcome is a further steady development of new antiviral agents which approach the "magic bullets" first proposed by PAUL EHRLICH. Remarkable advances in protein synthetic methods that yield polypeptides which inhibit active sites of viral proteins have aided substantially in the basic and clinical study of these antiviral agents. In addition, the extremely rapid progression in recombinant DNA techniques, leading to the synthesis of large quantities of gene products, is also increasing our opportunities at a dashing pace. New information and developing technology facilitate research on the mechanism of action, toxicity, pharmacokinetics, and pharmacodynamics of new agents. The list of clinically effective antiviral agents is expanding and the number of potentially useful compounds is growing rapidly. This book is a combined theoretical text and practical manual which, it is hoped, will be of use to all who have an interest in virus diseases, particularly scientists, physicians and graduate students.

Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in cubation period of active HIV infection, when the infection is clinically latent, is now un derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.

Considerable advances have been made in the treatment of antiviral diseases over the last decade. Several new drugs have been introduced while new clinical information has been gathered on the efficacy of existing drugs. This study aims to provide an examination of the basic science (drug formulae, structure and biochemical activity) and clinical information (usage and efficacy) on chemotherapy, as well as describing future potentials.

Viral Pathogenesis: From Basics to Systems Biology, Third Edition, has been thoroughly updated to cover topical advances in the evolving field of viral pathogenesis, while also providing the requisite classic foundational information for which it is recognized. The book provides key coverage of the newfound ability to profile molecular events on a system-wide scale, which has led to a deeper understanding of virus-host interactions, host signaling and molecular-interaction networks, and the role of host genetics in determining disease outcome. In addition, the content has been augmented with short chapters on seminal breakthroughs and profiles of their progenitors, as well as short commentaries on important or controversial issues in the field. Thus, the reader will be given a view of virology research with perspectives on issues such as biomedical ethics, public health policy, and human health. In summary, the third edition will give the student a sense of the exciting new perspectives on viral pathogenesis that have been provided by recent developments in genomics, computation, modeling, and systems biology. - Covers all aspects of viral infection, including viral entry, replication, and release, as well as innate and adaptive immunity and viral pathogenesis - Provides a fresh perspective on the approaches used to understand how viruses cause disease - Features molecular profiling techniques, whole genome sequencing, and innovative computational methods - Highlights the use of contemporary approaches and the insights they provide to the field

The book covers up-to-date information on nucleosides and antiviral chemotherapy contributed by the world experts in the field of nucleoside. This book is the result of a meeting honoring Dr. Jack J. Fox, who was one of the pioneers in nucleoside chemistry and chemotherapy. This book consists of 15 excellent chapters in the area, which include topics from recent synthetic methodologies, nucleoside kinase implicated in chemotherapy and drug design, excellent reviews on antiviral agents, nucleoside metabolism/mode of action in parasites, new compounds under clinical and pre-clinical trials, IMPDH inhibitors to review on nucleoside prodrugs.

Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Oseltamivir; Editorial: The coming years will see GPs prescribing more of the new anti-influenza drugs in primary care, both in treating the most vulnerable patients and in preventing virus spread in families and elderly residential homes. Disease Overview: The threat from influenza is greatly increased in those with other chronic underlying medical conditions, particularly cardiovascular disease, diabetes and chronic obstructive pulmonary disease. Drug Review: Reported benefits of oseltamivir treatment include faster resolution of symptoms such as cough, fever and sore throat, plus a speedier return to good health, normal sleeping patterns and a restoration of activity to pre-illness levels. Improving Practice: We can only hope that government policy may shift over the coming years to encourage the routine vaccination of more children and adults.

Fenner and White's Medical Virology, Fifth Edition provides an integrated view of related sciences, from cell biology, to medical epidemiology and human social behavior. The perspective represented by this book, that of medical virology as an infectious disease science, is meant to provide a starting point, an anchor, for those who must relate the subject to clinical practice, public health practice, scholarly research, and other endeavors. The book presents detailed exposition on the properties of viruses, how viruses replicate, and how viruses cause disease. These chapters are then followed by an overview of the principles of diagnosis, epidemiology, and how virus infections can be controlled. The first section concludes with a discussion on emergence and attempts to predict the next major public health challenges. These form a guide for delving into the specific diseases of interest to the reader as described in Part II. This lucid and concise, yet comprehensive, text is admirably suited to the needs of not only advanced students of science and medicine, but also postgraduate students, teachers, and research workers in all areas of virology. - Features updated and expanded coverage of pathogenesis and immunity - Contains the latest laboratory diagnostic methods - Provides insights into clinical features of human viral disease, vaccines, chemotherapy, epidemiology, and control

Canine and Feline Infectious Diseases is a practical, up-to-date resource covering the most important and cutting-edge advances in the field. Presented by a seasoned educator in a concise, highly visual format, this innovative guide keeps you current with the latest advances in this ever-changing field. 80 case studies illustrate the clinical relevance of the major infectious disease chapters. - Well-organized Major Infectious Diseases chapters break down content by etiologic agent and epidemiology, clinical signs and their pathophysiology, physical examination findings, diagnosis, treatment and prognosis, immunity, prevention, and public health implications. - Over 80 case studies illustrate how the information provided can be applied in everyday practice. - Logical approach to laboratory diagnosis guides you through all the steps needed to accurately diagnose and treat viral, bacterial, fungal, protozoal, and algal diseases. - Practical protocols provided by expert clinicians guide you in the management of canine and feline patients suspected to have infectious diseases, including handling, disinfection, isolation, and vaccination protocols. - Over 500 full color images – geographic distribution maps, life cycle drawings, and hundreds of color photographs – visually illustrate and clarify complex issues. - Easy-to-understand tables and boxes make content quickly accessible, eliminating the need to sort through dense text for critical information in the clinical setting.

Well-respected and widely regarded as the most comprehensive text in the field, Antibiotic and Chemotherapy, 9th Edition by Drs. Finch, Greenwood, Whitley, and Norrby, provides globally relevant coverage of all types of antimicrobial agents used in human medicine, including all antiviral, antiprotozoan and anthelminthic agents. Comprehensively updated to include new FDA and EMEA regulations, this edition keeps you current with brand-new information about antiretroviral agents and HIV, superficial and mucocutaneous myscoses and systemic infections, management of the immunocompromised patient, treatment of antimicrobial resistance, plus coverage of new anti-sepsis agents and host/microbe modulators. Reference is easy thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Offer the best possible care and information to your patients about the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Stay current with 21 new chapters including the latest information on superficial and mucocutaneous mycoses, systemic infections, anti-retroviral agents, and HIV. Get fresh perspectives and insights thanks to 21 newly-authored and extensively re-written chapters. Easily access information thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Apply the latest treatments for anti-microbial organisms such as MRSA, and multi-drug resistant forms of TB, malaria and gonorrhea. Keep up on the latest FDA and EMEA regulations.